Orexo licenses respiratory program to AstraZeneca

01/29/2013 | PharmaTimes (U.K.)

Sweden's Orexo granted AstraZeneca the right to carry out further preclinical work and evaluation of compounds in its OX-CLI program targeted for respiratory diseases. AstraZeneca was also given the option to purchase the compounds in the program. The deal entitles Orexo to possible milestone fees and royalties.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ